Schaun wir mal...
Neuester,
zuletzt geles. Beitrag
Antworten | Hot-Stocks-Forum Übersicht Alle
Zurück
Weiter
1 2 3 4 5 6
Antworten | Hot-Stocks-Forum Übersicht Alle
Zurück
Weiter 1 2 3 4 5 6
Aktienzusammenlegung vollzogen
Beiträge: 149
Zugriffe: 39.741 / Heute: 4
Zugriffe: 39.741 / Heute: 4
|
Werbung
Entdecke die beliebtesten ETFs von Amundi
Lyxor Net Zero 2050 S&P World Climate PAB (DR) UCITS ETF Acc
Perf. 12M: +206,18%
Amundi Nasdaq-100 Daily (2x) Leveraged UCITS ETF - Acc
Perf. 12M: +82,31%
Amundi ETF Leveraged MSCI USA Daily UCITS ETF - EUR (C/D)
Perf. 12M: +64,89%
Amundi Japan TOPIX II UCITS ETF - EUR Hedeged Dist
Perf. 12M: +40,67%
Amundi MSCI India II UCITS ETF - EUR Acc
Perf. 12M: +38,52%
Response Biomedical Corporation Announces First Quarter Results
Strong financial improvement of refocused business
VANCOUVER, British Columbia--(BUSINESS WIRE)--Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) reported financial results for the first quarter ended March 31, 2011. Total revenues for the three-month period ended March 31, 2011 increased 59% to $2,470,560 compared to $1,549,479 for the same period last year.
Operating expenses for the three-month period ended March 31, 2011 decreased 37% to $1,733,458 from $2,747,614 for the same period last year. Net loss decreased by 48% to $1,382,205 or $0.04 per share. As at March 31, 2011, the Company had a working capital balance of $5,570,193 compared to $6,611,283 as at December 31, 2010.
“In the first quarter of 2011, we were realizing the benefits of the restructuring of the business that we began in late 2010,” commented S.Wayne Kay, CEO. “The significant reduction in our workforce and the focus on our cardiac business are reflected not only in significantly reduced costs but also in increased sales volumes. We are leveraging our expansion in China and Europe through our distribution partners. We expect to see continued growth in revenue in 2011 while maintaining our lean cost structure. We are making strides towards positive cash flow and profitability.”
www.businesswire.com/news/responsebio/20110511005457/en
Strong financial improvement of refocused business
VANCOUVER, British Columbia--(BUSINESS WIRE)--Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) reported financial results for the first quarter ended March 31, 2011. Total revenues for the three-month period ended March 31, 2011 increased 59% to $2,470,560 compared to $1,549,479 for the same period last year.
Operating expenses for the three-month period ended March 31, 2011 decreased 37% to $1,733,458 from $2,747,614 for the same period last year. Net loss decreased by 48% to $1,382,205 or $0.04 per share. As at March 31, 2011, the Company had a working capital balance of $5,570,193 compared to $6,611,283 as at December 31, 2010.
“In the first quarter of 2011, we were realizing the benefits of the restructuring of the business that we began in late 2010,” commented S.Wayne Kay, CEO. “The significant reduction in our workforce and the focus on our cardiac business are reflected not only in significantly reduced costs but also in increased sales volumes. We are leveraging our expansion in China and Europe through our distribution partners. We expect to see continued growth in revenue in 2011 while maintaining our lean cost structure. We are making strides towards positive cash flow and profitability.”
www.businesswire.com/news/responsebio/20110511005457/en
Mit 1000 Stück. Die nächsten 10K gibts schon wieder billiger.
....hoffe, dass sich hier mal was im positiven tut.
RBM sollte schleunigst mal ein schnell test entwickeln...
ich werde morgen mal mit denenTelefonieren.
:-)
ich werde morgen mal mit denenTelefonieren.
:-)
VANCOUVER, British Columbia--(BUSINESS WIRE)--Response Biomedical Corporation (TSX: RBM, OTCBB: RPIBF) reported financial results for the second quarter ended June 30, 2011. For the three month period ended June 30, 2011, total revenues increased 23% to $2,771,104 compared to $2,255,513, gross margin percentage from product sales increased to 35% from 14%, operating expenses decreased 30% to $1,490,930 from $2,123,585. The increase in gross margin and decrease in operating expenses resulted in a 61% decrease in the loss to $719,685 or $0.02 per share compared to $1,868,104 or $0.07 per share in the same period last year.
“Significant quarter to quarter fluctuation in revenue has been our history and we expect this to continue through the remaining quarters in 2011. The largest factor driving this fluctuation is the timing of the distribution of products to our major China market.”
For the six month period ended June 30, 2011, total revenues increased 38% to $5,241,663 compared to $3,804,992, gross margin on product sales increased to 24% from 13%, operating expenses decreased 34% to $3,224,388 from $4,871,200. Net loss decreased by 54% to $2,101,891 or $0.05 per share from $4,528,152 or $0.18 per share in the same period in the prior year.
“Significant quarter to quarter fluctuation in revenue has been our history and we expect this to continue through the remaining quarters in 2011. The largest factor driving this fluctuation is the timing of the distribution of products to our major China market.”
For the six month period ended June 30, 2011, total revenues increased 38% to $5,241,663 compared to $3,804,992, gross margin on product sales increased to 24% from 13%, operating expenses decreased 34% to $3,224,388 from $4,871,200. Net loss decreased by 54% to $2,101,891 or $0.05 per share from $4,528,152 or $0.18 per share in the same period in the prior year.
sorry Quelle vergessen
www.businesswire.com/news/responsebio/20110810005804/en
www.businesswire.com/news/responsebio/20110810005804/en
Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) today announced that S. Wayne Kay, the Chief Executive Officer of Response, has tendered his resignation as both an officer and director of Response, effective immediately.
Peter Thompson will serve as Executive Chairman and interim CEO. The board has retained an executive search firm to assist in identifying and hiring a new CEO as quickly as possible.
“The numerous contributions made by Mr. S.Wayne Kay during his tenure at Response are much appreciated by the board,” said Executive Chairman and interim CEO, Peter Thompson. “We thank Wayne for his leadership and wish him well in his future endeavours.”
www.bradenton.com/2011/08/12/3417451/...dical-corporation.html
Für mich das Beste was den Aktionären passieren konnte!!Endlich ein großer Brocken, glaube zuletzt waren es 600000$ Jahreseinkommen weg.
Und hier noch einiges zum interims CEO
Peter Thompson, M.D., is currently a Venture Partner with OrbiMed who brings over 20 years of industry experience to OrbiMed. He co-founded Trubion Pharmaceuticals, and served as CEO and Chairman from its inception through its IPO on NASDAQ and as a public company until his retirement in 2009. Dr. Thompson is the former Vice President & General Manager of Chiron Informatics at Chiron Corporation and held various executive positions at Becton Dickinson, including Vice President, Research and Technology Department of BD Bioscience. Dr. Thompson is a co-founder of iMetrikus, a clinical decision support company, where he served as CEO and Chairman. He is the founder and Managing Director of Strategicon Partners, an investment and management services company. Dr. Thompson is an Affiliate Professor of Neurosurgery at the University of Washington and serves as a Director of Anthera (NASDAQ: ANTH), CoDa Therapeutics, Methylgene (TSX: MYG), Principia Biosciences, and Response Biomedical (TSX: RBM). Dr. Thompson is an Ernst & Young Entrepreneur of the Year awardee, an inventor on numerous patents, and a board-certified internist and oncologist. He was on staff at the National Cancer Institute following his internal medicine training at Yale University. He received his medical and undergraduate degrees from Brown University.
www.orbimed.com/team_private_equity.htm
Jetzt hoffe ich nur, dass sie einen geeigneten CEO finden, der endlich auch mal an die Aktionäre und nicht nur an sich denkt.
Peter Thompson will serve as Executive Chairman and interim CEO. The board has retained an executive search firm to assist in identifying and hiring a new CEO as quickly as possible.
“The numerous contributions made by Mr. S.Wayne Kay during his tenure at Response are much appreciated by the board,” said Executive Chairman and interim CEO, Peter Thompson. “We thank Wayne for his leadership and wish him well in his future endeavours.”
www.bradenton.com/2011/08/12/3417451/...dical-corporation.html
Für mich das Beste was den Aktionären passieren konnte!!Endlich ein großer Brocken, glaube zuletzt waren es 600000$ Jahreseinkommen weg.
Und hier noch einiges zum interims CEO
Peter Thompson, M.D., is currently a Venture Partner with OrbiMed who brings over 20 years of industry experience to OrbiMed. He co-founded Trubion Pharmaceuticals, and served as CEO and Chairman from its inception through its IPO on NASDAQ and as a public company until his retirement in 2009. Dr. Thompson is the former Vice President & General Manager of Chiron Informatics at Chiron Corporation and held various executive positions at Becton Dickinson, including Vice President, Research and Technology Department of BD Bioscience. Dr. Thompson is a co-founder of iMetrikus, a clinical decision support company, where he served as CEO and Chairman. He is the founder and Managing Director of Strategicon Partners, an investment and management services company. Dr. Thompson is an Affiliate Professor of Neurosurgery at the University of Washington and serves as a Director of Anthera (NASDAQ: ANTH), CoDa Therapeutics, Methylgene (TSX: MYG), Principia Biosciences, and Response Biomedical (TSX: RBM). Dr. Thompson is an Ernst & Young Entrepreneur of the Year awardee, an inventor on numerous patents, and a board-certified internist and oncologist. He was on staff at the National Cancer Institute following his internal medicine training at Yale University. He received his medical and undergraduate degrees from Brown University.
www.orbimed.com/team_private_equity.htm
Jetzt hoffe ich nur, dass sie einen geeigneten CEO finden, der endlich auch mal an die Aktionäre und nicht nur an sich denkt.
Liege bei 85 % verlust! Ich hätte nie gedacht, dass die Bude so absäuft! Man hört auch nicht mehr viel! Weiß jemann mehr?
Heute werden die Zahlen veröffentlicht, schauen wir mal
VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 26, 2012) - Response Biomedical Corporation (TSX:RBM)(OTCBB:RPBIF) will release its fourth quarter and fiscal year 2011 financial results after markets close on Wednesday, March 28, 2012.
Dr. Peter A. Thompson, Executive Chairman and interim CEO, will host a conference call shortly following the release of the financial results on March 28, 2012 at 3.00 p.m. PST (6.00 p.m. EST) to discuss these financial results for the fourth quarter and fiscal year 2011.
www.stockhouse.com/News/CanadianReleasesDetail.aspx?n=8462107
VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 26, 2012) - Response Biomedical Corporation (TSX:RBM)(OTCBB:RPBIF) will release its fourth quarter and fiscal year 2011 financial results after markets close on Wednesday, March 28, 2012.
Dr. Peter A. Thompson, Executive Chairman and interim CEO, will host a conference call shortly following the release of the financial results on March 28, 2012 at 3.00 p.m. PST (6.00 p.m. EST) to discuss these financial results for the fourth quarter and fiscal year 2011.
www.stockhouse.com/News/CanadianReleasesDetail.aspx?n=8462107
www.responsebio.com/fullNews.asp?id=29
(RTTNews) - Response Biomedical Corp. (RPBID.OB,RBM.TO:Quote) announced that it has regained the worldwide rights to Flu A+B and RSV testing products as a result of the termination of its collaboration with 3M Company and 3M Innovative Properties Company including agreements for the Joint Development, Supply, and Distribution of RAMP - based products.
In addition, Response will acquire 3M's entire remaining inventory of RAMP readers and peripheral devices, assignment of its distributor network and all marketing materials used by 3M in connection with the marketing and sale of Response products.
www.rttnews.com/1976266/...d-rsv-testing-products.aspx?type=qf
In addition, Response will acquire 3M's entire remaining inventory of RAMP readers and peripheral devices, assignment of its distributor network and all marketing materials used by 3M in connection with the marketing and sale of Response products.
www.rttnews.com/1976266/...d-rsv-testing-products.aspx?type=qf
Kanada (Toronto Stock Exchance) legt vor, Europa zieht nach. Das mit der Nasdaq war ein Fehler von mir - Entschuldigung.
Aber der Wert hat seit mitte November um 100 % zugelegt.
Aber der Wert hat seit mitte November um 100 % zugelegt.
|
Neueste Beiträge aus dem Response Biomedical Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 148 | Aktienzusammenlegung vollzogen | Laie123 | DaxiDowi | 07.02.13 08:40 | ||
2 | 10 | Response Biomedical- Wiedergeburt in 2011 | doschauher | doschauher | 28.01.11 18:16 | |
| 9 | 1.008 | Response Biomedical - Zukunftswert | fuerza_hercuela | Benull | 18.06.10 00:04 | |
| 6 | auf neue höhen | ARTNER514 | Benull | 08.01.10 13:37 | ||
| 4 | mind. 100% schanze | micha1 | hausl | 25.10.09 21:56 |